Published in Lancet on January 15, 1977
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut (1987) 1.38
Tumour markers in breast cancer. Br J Cancer (1979) 1.13
Monocyte maturation and prognosis in primary breast cancer. Br Med J (1979) 1.01
Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer (1993) 0.92
Humoral innate immune response and disease. Clin Immunol (2012) 0.89
Evaluation of biochemical markers in breast cancer. Proc R Soc Med (1977) 0.85
Relationship of total serum sialic acid to sialylglycoprotein acute-phase reactants in malignant melanoma. Br J Cancer (1980) 0.85
Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation (2009) 0.84
Serum proteins as tumour markers for breast cancer. Br J Cancer (1981) 0.77
Tumour markers in breast cancer. Br Med J (1979) 0.75
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma. Br Med J (1972) 5.48
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Bone disease after jejuno-ileal bypass for obesity. Lancet (1978) 3.84
A shorter immunoperoxidase technique for the demonstration of carcinoembryonic antigen and other cell products. J Clin Pathol (1977) 3.77
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Distribution of epithelial membrane antigen in normal and neoplastic tissues and it value in diagnostic tumor pathology. Cancer (1981) 3.07
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
Foetal antigens and their role in the diagnosis and clinical management of human neoplasms: a review. Br J Cancer (1972) 2.53
Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol (1999) 2.52
The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer (1980) 2.50
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
A simplified method of detection of clonal rearrangements of the T-cell receptor-gamma chain gene. Diagn Mol Pathol (1992) 2.33
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol (1999) 2.32
Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet (1974) 2.30
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol (1982) 2.17
Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Intern Med J (2003) 2.16
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer (1992) 2.10
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res (1982) 2.07
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Rapid method for distinguishing clonal from polyclonal B cell populations in surgical biopsy specimens. J Clin Pathol (1990) 2.03
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol (2002) 1.91
Hypertension with aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour. Lancet (1970) 1.90
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci U S A (2001) 1.87
Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res (1994) 1.84
Biochemical monitoring of cancer. A review. Ann Clin Biochem (1976) 1.83
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia (2000) 1.79
Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr (1981) 1.79
Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell (2000) 1.77
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Diagnosing breast carcinoma in young women. BMJ (1991) 1.71
Role of serial plasma C.E.A. assays in detection of recurrent and metastatic colorectal carcinomas. Br Med J (1974) 1.69
Monoclonal antibodies to the human mammary gland. I. Distribution of determinants in non-neoplastic mammary and extra mammary tissues. Virchows Arch A Pathol Anat Histol (1982) 1.68
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Recurrent Cancer of Head and Neck. Br Med J (1962) 1.63
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol (1995) 1.61
Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol (1999) 1.60
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Effect of antilymphocyte serum on the growth of Hep 2 and HeLa cells in mice. Nature (1968) 1.58
Are breast cancer axillary node micrometastases worth detecting? J Pathol (1990) 1.57
Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol (1995) 1.57
Treatment of gross obesity by jejunal bypass. Br Med J (1974) 1.55
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
The rapid detection of clonal T-cell proliferations in patients with lymphoid disorders. Am J Pathol (1991) 1.53
Topical calcipotriol treatment in advanced breast cancer. Lancet (1991) 1.53
Evaluation of sensitivity, specificity, and reproducibility of an optimized method for detecting clonal rearrangements of immunoglobulin and T-cell receptor genes in formalin-fixed, paraffin-embedded sections. Diagn Mol Pathol (1993) 1.52
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46